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Abstract. Helicobacter pylori is one of the human pathogens with 
highest prevalence around the world. Colonizing the human 
stomach, H. pylori could lead to peptic ulceration, gastric 
adenocarcinoma and gastric lymphoma. H. pylori is a genetically 
diverse bacterial species, and variability in virulence factors has a 
role in bacterial pathogenesis and progression to gastric cancer, 
although bacterium and host factors of progression are not 
completely understood. In a recent study, we have demonstrated 
that six housekeeping genes related to H. pylori pathogenesis were 
specifically amplified for H. pylori in a total of 52 H. pylori clones 
isolated from 11 patients. Although most clones isolated from the 
same patient showed identical gene sequences, events of multiple 
infection and microevolution were detected. We consider that 
housekeeping genes could be useful for H. pylori detection            
and to elucidate the mode of transmission and the relevance of the  
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multiple infection. Further genetic studies are required to provide powerful tools to 
face all current unmet challenges of H. pylori infection, such as the elucidation of 
mode of transmission, the development of new sensitive and specific PCR methods 
for H. pylori detection, and implication of H. pylori in other diseases. 
 
Introduction 
 
      H. pylori is one of the human pathogens with highest prevalence around 
the world (50% of the world´s population, with proportions as high as 80% 
in developing countries) [1,2], which was first isolated in culture media by 
Warren and Marshall in 1982. This Gram negative, spiral-shaped, 
microaerophilic bacterium, with positive findings for urease, oxidase and 
catalase, colonizes the human gastric epithelium [2,3], where it can be found 
in two forms, the bacillary and coccoid forms [4]. H. pylori is difficult to 
culture in vitro, particularly in liquid media, being its growth demonstrated 
in several nutrient-rich media at 37ºC [5]. 
 H. pylori is a genetically diverse bacterial species, and variability in 
virulence factors has a role in bacterial pathogenesis [6,7]. Accumulating 
evidences support that H. pylori infection cause a list of diseases, ranging 
from gastric to extra-gastric diseases, from chronic gastritis to gastric 
carcinoma, and thus this bacterium is recognized as Class I  carcinogenic 
pathogen in humans [8,9]. Gastric adenocarcinoma is the second highest 
cause of cancer deaths worldwide. The nearly one million deaths per year are 
due to a combination of high incidence, aggressive disease course, and lack 
of effective treatment options. H. pylori causes distal but not proximal 
gastric adenocarcinoma, distal being the most common form. H. pylori also 
causes B cell mucosa-associated lymphoid tissue (MALT) lymphoma of the 
stomach [3,10]. 
 Progression from initial gastritis toward more severe disease such as 
gastric cancer occurs only in a small proportion of the infected individuals 
and is likely to depend on host factors, exposure to lifestyle factors, and 
bacterial factors [1,7,10]. Furthermore, epidemiological and eradication 
studies have demonstrated a casual relationship between H. pylori infections 
and endothelial dysfunction, leading to vascular diseases [3,11]. It has also 
been suggested the possible association of H. pylori infection with several 
extragastric effects, including hepatobiliary and pancreatic diseases, 
although further research is needed in this issue [12].  
 H. pylori colonization usually occurs in childhood, particularly in 
developing areas, and usually in the same family for a cohort effect [3], but 
infection persists lifelong in the absence of treatment. H. pylori persistence is 
central to pathogenesis; ulcers occur mainly in mid- or late adulthood after 
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many years of infection and inflammation, and gastric adenocarcinoma 
occurs in late adulthood after an even longer period of chronic inflammation 
and epithelial damage [10]. 
 H. pylori strains appear to be spread by person-to-person contact and 
DNA fingerprinting has provided evidence of transmission between family 
members [13]. To date, however, the exact mode of transmission is still 
uncertain. While this organism is isolated from the human stomach, it has 
not been consistently isolated from other niches, and thus the mechanism by 
which it colonizes the human stomach remains largely unknown [2]. 
 Different invasive and non-invasive diagnostic tests are available for the 
diagnosis of H. pylori in the individual patient. The non-invasive tests 
obviate the need for endoscopy and can be surely more accepted by the 
subjects [3]. Therefore, further research is needed to improve non-invasive 
methods, mainly based on PCR methods.  
 The goal of H. pylori treatment is the complete elimination of the 
organism. Once this has been achieved, reinfection rates are low; thus, the 
benefit of treatment is durable [14]. Curing the infection interferes with the 
precancerous cascade if accomplished early in the process, and can prevent 
cancer development [15]. The so-called triple therapies, combinations of one 
antisecretory agent with two antimicrobial agents for 7 to 14 days, have been 
extensively evaluated and approved [14]. Failure of antibiotic treatment, 
often caused by antibiotic resistant H. pylori strains, however, is frequent 
[14] and appears to be increasing, so susceptibility testing for antibiotics 
plays an important role in treatment [16]. 
 The recent findings on the bacterial virulence factors, effects of                   
H. pylori on epithelial cells, genetic polymorphism of both the bacterium and 
its host, and the environmental factors can help to understand the role of this 
bacterium in gastric carcinogenesis [9]. However, more research is needed to 
globally face this prevalent infection, such as: to screen and treat only strains 
that are known to cause disease, the elucidation of mode of transmission, 
implication of H. pylori in other diseases, the role of mixed infections, the 
development of new sensitive and specific PCR methods for H. pylori 
detection in gastric samples and other specimens, and the development of a 
safe and efficient preventive vaccine that could address the wide diversity of 
strains.  
 
1. Epidemiology and population genetics of H. pylori 
 
 H. pylori is one of the most common bacterial infectious agents; it 
inhabits the stomachs of more than half of the world’s population. The 
prevalence of H. pylori infection is decreasing in developed countries as 
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showed by the lower prevalence in the younger generations. In north 
European and North American populations, about one-third of adults are still 
infected, whereas in south and east Europe, South America, Africa, and 
Asia, the prevalence of H. pylori is often higher than 50%. These 
prevalences may differ between different ethnic, social or age groups within 
the same country [2,10,17]. The prevalence of infection seems to mostly 
depend on the rate of acquisition, but also on the rate of loss of infection and 
the length of the persistence period between acquisition and loss [2]. Several 
factors have been associated with H. pylori infection as a low socioeconomic 
status, living in a rural area, in crowded homes, and having contaminated 
sources of drinking water [17].  
 Despite the high prevalence of H. pylori infection in Africa and South 
Asia, the incidence of gastric cancer in these areas is much lower than in 
other countries. Furthermore, the incidence of gastric cancer tends to 
decrease from north to south in East Asia. Such geographic differences in the 
pathology can be explained, at least in part, by the presence of different 
types of H. pylori virulence factors determinants, especially cagA, vacA 
genes, and the right end of the cag pathogenicity island. The genotype of the 
virulence genes is useful not only for the study of gastroduodenal diseases 
related to H. pylori but also as a tool to track human migration although with 
less accuracy than the multilocus sequence typing (MLST) [18].  
 MLST analysis using seven housekeeping genes (atpA, efp, mutY, ppa, 
trpC, ureI, and yphC) is useful to predict the history of human migrations 
and may be at least as informative as most human genetic markers [18,19]. 
H. pylori is ubiquitous and possesses strong phylogeographic structure, 
suggesting that bacterial polymorphisms reflect human phylogeography and 
historical migrations. Population structure analysis based on MLST has 
revealed seven modern population types of H. pylori (Fig. 1): hpEurope, 
hpAfrica1 (with two subpopulations, hspSAfrica, and hspWAfrica), 
hpAfrica2, hpAsia2, hpEastAsia (with three subpopulations, hspAmerind 
hspEAsia, and hspMaori), hpNEAfrica, and hpSahul [18,20,21,22,23].  
 The geographic sources of the different strains isolated reflect major 
events in human settlement history (Fig. 1), such as the colonization of 
Polynesia and the Americas and the African Bantu migrations. Like humans, 
simulations indicate that H. pylori seems to have spread from east Africa 
around 58,000 years ago. Therefore, these data indicate that anatomically 
modern humans were already infected by H. pylori before their migrations 
from Africa and demonstrate that H. pylori has remained intimately 
associated with their human host populations ever since [20,21,22,23]. 
 The existing European population of H. pylori is known to be a hybrid 
between Asian and African bacteria, although there are hypotheses about 
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when and where the hybridization took place. In a recent study, a 5300-year-
old H. pylori genome from a European Copper age glacier mummy was 
determined and reconstructed. Results obtained showed that the ―Iceman‖            
H. pylori was a nearly representative of the bacterial population of Asian 
origin that existed in Europe before hybridization, suggesting that the 
African population arrived in Europe within the past few thousand years 
[24]. 
 
 
 
Figure 1. Distribution of Helicobacter pylori genotypes before Columbus found the 
New World and human migration to America and Oceania began. There are seven 
modern H. pylori population types—hpEurope, hpEastAsia, hpAfrica1, hpAfrica2, 
hpAsia2, hpNEAfrica and hpSahul. hpEurope includes almost all H. pylori strains 
isolated from ethnic Europeans, including people from countries colonized by 
Europeans. Most H. pylori isolates from East Asia belong to hpEastAsia, which 
includes hspMaori (Polynesians, Melanesians, and native Taiwanese), hspAmerind 
(American Indians) and hspEAsia (East Asia) subpopulations. hpAsia2 strains are 
isolated in South, Southeast and Central Asia; hpAfrica1 in west Africa, South Africa 
and African Americans. hpNEAfrica is predominantly made up of isolates from 
Northeast Africa. hpAfrica2 is very distinct from any other type and has currently 
only been isolated in South Africa. hpSahul is a novel group specific to H. pylori 
strains isolated from Australian Aborigines and Highlanders of New Guinea.                    
H. pylori is predicted to have spread from East Africa over the same time period as 
anatomically modern humans (~58,000 years ago), and has remained intimately 
associated with their human hosts ever since. Estimated global patterns of H. pylori 
migration are indicated by arrows and the numbers show the estimated time since 
they migrated (years ago). The broken arrow indicates an unconfirmed migration 
pattern. (reprinted by permission from Macmillan Publishers Ltd: ref. [23], copyright 
2010).  
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 Elucidation of the pattern of population subdivision is also of medical 
interest. Geographically variable results regarding the association of putative 
virulence factors with disease might well reflect differences in the local 
prevalence of the individual H. pylori populations. Similarly, the 
development of diagnostic tests, antibiotics, and vaccines needs to account 
for global diversity and will be aided by the availability of representative 
isolates [20]. 
 
2. Transmission of H. pylori infection 
 
 Currently, the majority of available evidence points to the transmission 
of H. pylori from human-to-human. The exact route of transmission from 
person-to-person is still unknown. Ingestion of the bacteria, which is the 
most likely portal of entry, may occur by one or a combination of three 
means: oral-oral, gastro-oral, or fecal-oral. However, determination of the 
dominant route has not been possible to date [2]. 
 H. pylori has been detected in dental plaque and saliva, suggesting that 
the oral cavity may be an extra-gastric reservoir and play an important role 
in both transmission and recurrence [25]. Since the human stomach is the 
primary niche of H. pylori, it is reasonable to suggest a direct gastro-oral 
route of transmission mediated by refluxed gastric juice. This hypothesis is 
supported by studies showing the presence of H. pylori in the gastric juice, 
as vomitus [2,26,27]. 
 Although H. pylori is sensitive to the bile’s bactericidal effect, different 
studies have detected viable H. pylori in stools [2,28,29], thus supporting the 
fecal-oral route of transmission. 
 H. pylori has also been detected in environmental or animal reservoirs, 
although it has not been demonstrated yet if they are natural or primary 
vehicles of transmission [2]. 
 Presence of H. pylori has been detected in un-washed vegetables, as 
leek, traditional salad, basil or lettuce [30]. More research is needed to 
establish different foods at high risk of H. pylori presence and transmission.  
 Moreover, the demonstration of transmission of viable cells is even 
more complicated taking into account the difficulties of the bacterium to 
grow in vitro [5]. 
 
3. Role of Helicobacter pylori infection in pathogenesis of gastric 
carcinoma 
 
 The gastric mucosa is well protected against bacterial infections because 
of its acidic milieu that acts as a first line of defense against food-borne 
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microbes. In addition, the reflux of bile acids in the stomach, the thickness of 
the mucus layer, and the effectiveness of gastric peristalsis might have 
impeded bacterial colonization of the stomach. Nevertheless, H. pylori is 
highly adapted to this ecological niche, with a unique array of features that 
permit entry into the mucus, swimming and spatial orientation in the mucus, 
attachment to epithelial cells, evasion of the immune response, and, as a 
result, persistent colonization and transmission [14]. 
 For colonization and survival in the human stomach all Helicobacter 
isolates require urease and flagella. Urease metabolizes urea to carbon 
dioxide and ammonia to buffer the gastric acid. Flagella allow the bacterium 
to swim across the viscous gastric mucus and reach the more neutral pH 
below the mucus. H. pylori may use at least five different adhesins to attach 
to gastric epithelial cells. Adhesion by adhesins to epithelial gastric cells is 
important for the beginning of infection and for the enhanced inflammatory 
response. Following colonization, H. pylori must acquire nutrients from the 
gastric mucosa, in which the acquisition of iron from the host is particularly 
important [3]. 
 In most infected people, the bacterium acts as a commensal organism 
inducing chronic asymptomatic gastritis that can last for life. In other cases, 
however, it is responsible for a high morbidity and mortality as a 
consequence of peptic ulcers and gastric cancer. Chronic gastritis may 
progress to intestinal metaplasia, dysplasia and eventually gastric cancer 
(Fig. 2), a multi-step process known as the Correa pathway [15,31]. H. pylori 
infection is the strongest known risk factor for gastric cancer, as supported 
by epidemiological, preclinical and clinical studies [9,14]. In fact, gastric 
cancer is the fourth cause of death because of a cancer in Europe 
(GLOBOCAN 2012; http://globocan.iarc.fr/).  
 However, the mechanism of H. pylori developing gastric carcinoma has 
not been well defined. Among infected individuals, approximately 10% 
develop severe gastric lesions such as peptic ulcer disease and 1–3% 
progresses to gastric cancer. The outcomes of H. pylori infection are 
determined by bacterial virulence, genetic polymorphism of both hosts and 
bacteria, as well as environmental factors [9,31]. Environmental factors, 
such as cigarette smoking, are major risk factors for duodenal ulceration 
among H. pylori-infected people [3]. Other important factors include stress, 
childhood living conditions, diet, alcohol and use of non-steroidal anti-
inflammatory drugs (NSAIDs) [3,31,32]. 
 H. pylori infection commonly lasts for decades, provoking a series of 
histological changes including destruction of intercellular junctions, 
apoptosis and proliferation of epithelial cells and malignant transformation 
(Fig. 3) [9,33,34]. The genotypes of H. pylori strains, host genetic 
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polymorphisms, environmental factors like high salt diet, smoking habit and 
certain gastric commensal organisms have been determined to be associated 
with occurrence of gastric cancer. H. pylori genetic polymorphisms, effects 
of specific H. pylori products on gastric epithelium and cellular signaling 
process have been intensively investigated in recent decades [9,35]. 
 
 
 
Figure 2. Natural history of H. pylori infection. H. pylori is usually acquired in 
childhood, whereas acute infection with the bacterium is rarely diagnosed. Instead, 
chronic gastritis develops in almost all persistently colonized individuals, 90% of 
whom will remain asymptomatic. The clinical course of H. pylori infection is highly 
variable depending on bacterial and host (genetic and immune) factors. Recent 
studies have supported the possible role of bone marrow-derived cells (i.e., gastric 
stem cells) in tumor progression. Patients with increased acid secretion are more 
likely to have antral-predominant gastritis, which predisposes to duodenal ulcers. 
Patients with low acid secretion will more likely develop gastritis in the body of the 
stomach and are thus more likely to develop gastric ulcer, leading to gastric atrophy, 
intestinal metaplasia, dysplasia and, finally, in rare cases, gastric carcinoma. This 
sequence of events is more frequent in people of advanced age. H. pylori infection 
induces the formation of mucosa-associated lymphoid tissue (MALT) in the gastric 
mucosa and MALT lymphoma is another rare complication of H. pylori infection. 
(reprinted by permission from Spandidos Publications: ref. [31], copyright 2013).  
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 Besides its arsenal of virulence factors, persistence of H. pylori is 
strongly influenced by the ability of the bacterium to evade, overthrow and 
manipulate the host’s immune system. This bacterium can evade detection 
by several innate immune receptors through target modification and it can 
subvert other innate recognition pathways through the suppression of 
downstream signal transduction, whereas evasion of adaptive immunity is 
achieved by the modulation of effector T cell functions [36]. 
 Despite the host’s vigorous immune response, H. pylori is capable of 
persisting for decades in its human host. Interestingly, coccoid forms appear 
to be the persisting form, allowing H. pylori to spread between human hosts. 
It has been shown that the morphological transition from bacillary to coccoid 
forms is accompanied by modifications of the bacterial cell wall 
peptidoglycan, in which AmiA protein is essential. Cell wall modifications 
and morphological transition allow the coccoid forms to escape detection by 
the immune system and therefore could participate in the persistence of                   
H. pylori infection during the lifetime of its human host [4]. 
 
 
 
Figure 3. The pathogenesis of Helicobacter pylori-associated gastric cancer is a 
multi-factorial process, its development depends on a combination of host, bacterial 
and environmental factors, and the pathological changes might progress in steps. 
(reprinted by permission from Baishideng Publishing Group Inc.: ref. [9], copyright 
2016).  
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4. H. pylori virulence factors 
 
 Crucial bacterial factors associated with pathogenicity comprise flagella, 
urease, peptidoglycan, lipopolysaccharide (LPS), Hsp60 (= Cpn60) 
chaperone, a type IV secretion system encoded by the cag pathogenicity 
island containing the effector protein CagA, the vacuolating cytotoxin 
(VacA), and others [37]. 
 The high number of these factors and allelic variation of the involved 
genes generates a highly complex scenario and reveals the difficulties in 
testing the contribution of each individual factor. Much effort has been put 
into identifying the molecular mechanisms associated with H. pylori-
associated pathogenesis using human primary tissues, Mongolian gerbils, 
transgenic, knockout and other mice, as well as in vitro cell model systems 
[37]. 
 Studies on H. pylori heterogeneity have proved that the strongest 
virulence factors were amongst the genes within the cag pathogenicity island 
(PAI). The mechanisms underlying H. pylori-related gastric carcinogenesis, 
however, remain unclear [9], with the virulence factors CagA and VacA 
having a prominent role.  
 Development of gastric and hematological carcinoma has been observed 
in the mice that were genetically modified to express CagA [9,38]. Studies 
revealed that cagA+/vacAs1+/vacAm1+ H. pylori strains promoted 
pathogenesis of intestinal metaplasia and gastric carcinoma [9,39]. 
 
4.1. Flagella 
 
 H. pylori possess two to six sheathed unipolar flagella, which confer 
motility and constitute a virulence factor shown to be absolutely essential for 
colonization [40]. Non-motile mutants lacking flagella are unable to 
establish persistent infection in animal models [40,41,42], although it has 
also been shown that the presence of flagella alone is not sufficient for 
colonization [40,43] 
 
4.2. Urease 
 
 Urease can play a broad role in the pathogenesis associated with                      
H. pylori infection. Although urease is known for its enzymatic activity 
(converts urea into ammonia and bicarbonate to counteract the low acidity of 
the stomach), it is also correlated with the dual function of adhesivity and 
immunogenicity [3,44]. 
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4.3. Peptidoglycan 
 
 The mechanism by which H. pylori generates helical shape is unknown. 
A novel study identified four genes being involved: peptidoglycan 
endopeptidases (csd1-3) and ccmA. The findings suggest that the coordinated 
action of multiple proteins relaxes peptidoglycan crosslinking, enabling 
helical cell curvature and twist, which is required for robust bacterial 
colonization in the stomach [35,45]. 
 
4.4. Lipopolysaccharide 
 
 O polysaccharides of the gastric pathogen H. pylori contain Lewis 
antigens, mimicking glycan structures produced by human cells. The 
interaction of Lewis antigens with human dendritic cells induces a 
modulation of the immune response, contributing to the H. pylori virulence. 
The amount and position of Lewis antigens in the LPS varies among                    
H. pylori isolates, indicating an adaptation to the host [46]. 
 Two new enzymes typically involved in LPS biosynthesis were 
discovered in H. pylori, glycosyltransferase WecA and O-antigen ligase 
WaaL, but a flippase enzyme, normally involved in O-antigen synthesis, 
could not be detected. Instead, H. pylori uses a translocase named Wzk in a 
novel LPS biosynthetic pathway, evolutionarily connected to protein          
N-glycosylation [35,46]. In addition, 3-deoxy-d-manno-octulosonic acid 
(Kdo) hydrolase genes (HP0579 and HP0580) were shown to affect the 
expression of O-antigen Lewis epitopes [47]. Finally, an ADP-l-glycero-d-
manno-heptose-6-epimerase ortholog (HP0859) was characterized. 
DHP0859 mutants exhibited severe truncation of LPS, decreased growth 
rate, higher susceptibility to novobiocin, and failed to induce the AGS 
elongation phenotype in AGS cells. Genetic complementation restored these 
phenotypes, revealing HP0859 essential for LPS biosynthesis and virulence 
[35,48]. 
 
4.5. Hsp60 superficial protein 
 
 H. pylori produces two heat shock proteins (Hsps): a groEs-like HspsA 
(size 13 kD) and groEL-like HspsB (size 54–60 kD, Hsps60). Hsps60 is in 
particular shared by H. pylori and eukaryotic cells [3,49]. The homologies 
between bacteria and human Hsp60 antigens leads to an antibody response 
directed to both the bacteria and to human tissues that express Hsps, 
including vascular endothelial cells (autoimmune response) [3]. 
Núria Piqué  et al. 176 
4.6. CagA 
 
 CagA, a highly immunogenic protein, is encoded at one end of the cag 
PAI, which encode the components to form the type IV secretion system 
(T4SS) [7,9,50]. As a component of T4SS, CagL protein binds to and 
activates the integrin α5β1 receptor on gastric epithelial cells and triggers 
CagA delivery into the target cells [9,51].  
 H. pylori strains harboring the cag PAI or producing CagA are related 
to enhanced inflammation and risk of ulcers and carcinoma [9,52,53]. 
Moreover, the C-terminal EPIYA-containing region of CagA is 
polymorphic and isolates from gastric cancer patients frequently have a 
high number of EPIYA motifs [54]. CagA contributes to myriad signaling 
alterations, which profoundly affects physiology of host epithelial cells [9]. 
 Once inside host cells, CagA is tyrosine phosphorylated, triggering the 
cellular signaling pathways leading to expression of proinflammatory 
cytokines and chemokines, and deregulates the signaling pathways that 
control host cell shape, adhesion and transformation [9,35,55].  
 Unphosphorylated CagA interacts with certain intracellular proteins, 
up-regulate production of proinflammatory cytokines, provoke mitogenic 
responses and disrupt intercellular junctions and epithelial cell polarity 
[9,55,56]. Additionally, CagA intoxicates dendritic cells leading to 
impaired activation, decreased inflammatory cytokine production and Th1 
immune response [9,57]. Recently, it was confirmed that H. pylori 
infection resulted in rapid association of the virulence factor CagA with 
the c-Met receptor, activation of signaling and epithelial proliferation 
[9,58]. 
 
4.7. Vacuolating cytotoxin A 
 
 Vacuolating cytotoxin A (VacA) is a bacterial toxin with multiple 
activities, contributing to multiple structural and functional alterations of 
epithelial cells [7,9]. After secretion by the bacterium through the type V 
secretion system, VacA binds to host cells interfering with endosomal 
maturation and leading to vacuolation, enhances leakage of nutrients by 
destruction of barrier function at tight junctions of epithelial cells, 
provokes mitochondrial damage and cell apoptosis, which improves                    
H. pylori growth [9,59,60,61]. Recent studies proved that VacA could 
disrupt phagocytosis, interfere with antigen presentation, restrain T cell 
activation in vitro and inhibit T cell proliferation independing of NFAT 
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(nuclear factor of activated T cells) activation or IL-2 expression 
[9,62,63,64]. These effects of VacA on the immune system may explain 
how H. pylori evades adaptive immune responses to establish persistent 
infection [9]. 
 The secreted mature form of VacA is a 88 kDa monomer comprising 
two domains designated p33 (residues 1–311) and p55 (residues 312–821) 
[65]. VacA harbours different allelic variants that modulate its activity. 
The amino-terminal end of VacA (residues -33–1), designated as the signal 
peptide or ―s-region‖, carrying the s1 or s2 alleles; the intermediate region 
or ―i-region‖ that encodes part of the p33 (residues 190–223) with the 
allelic variants i1 or i2; and the mid region or ―m-region‖, existing as an 
m1 or m2 allele [7,65,66]. Mosaic combinations of the s-, i- and m-regions 
exist and relate to the in vitro cytotoxin activity. Strains with alleles 
s1/i1/m1 have been associated with peptic ulcer disease and gastric cancer 
[67]. González et al. (2011) [7] showed that patients infected with high 
virulence strains (cagA+, vacA s1i1m1) have a higher risk of progression 
of the preneoplastic lesions to gastric cancer in relation to patients infected 
with low virulence strains. 
 
4.8. Other virulence factors 
 
 Adherence to epithelial cells is essential for H. pylori colonization and 
delivery of virulence factors to host cells. Some H. pylori adhesins have 
been described, including the sialic acid-binding adhesins BabA and SabA 
[9,68,69], and OipA, an inflammation-related outer membrane protein 
[9,70]. Other outer membrane proteins (OMPs) as HomA and HomB have 
been associated with peptic ulcer disease (PUD) [3,71,72]. The development 
of duodenal ulcer has also been correlated to the presence of the duodenal 
ulcer promoting gene A (dupA), but its role in gastric cancer is controversial 
[70]. 
 Other H. pylori virulence factors described are HrgA, GGT, HP-NAP, 
HopQ, etc. Restriction endonuclease-replacing gene A (hrgA) is considered 
as an important virulence determinant in H. pylori-associated gastric 
diseases such as carcinoma [3,73,74]. GGT is a gamma-glutamyl 
transpeptidase related to increased levels of hydrogen peroxide and IL-8 in 
epithelial cells and H. pylori-associated diseases [9,75,76,77]. The H. pylori 
neutrophil-activating protein (HP-NAP) is another virulence determinant that 
stimulates neutrophil high production of oxygen radicals and adhesion to 
endothelial cells [3,78]. It has also been shown that the outer membrane 
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protein HopQ is involved in leukocyte migration inhibition, together with 
CagA, suggesting an unprecedented role of the HopQ-CagA axis in immune 
modulation [79]. 
 
5. Currently used diagnosis methods 
 
 In patients with H. pylori-related diseases, a reliable diagnosis of 
infection with this bacterium is crucial, but no single test can be considered 
the gold standard [80,81]. Testing for H. pylori infection is indicated in 
patients with active peptic ulcer disease, a past history of documented peptic 
ulcer, or gastric MALT lymphoma [82]. 
 Different invasive and non-invasive diagnostic tests are available for the 
diagnosis of H. pylori in the individual patient. The non-invasive tests 
obviate the need for endoscopy and can be surely more accepted by the 
subjects [3]. 
 Histology is usually considered to be the gold standard in the direct 
detection of H. pylori infection and is also the first method used for the 
detection of H. pylori. Several factors, however, influence the diagnostic 
accuracy of histology, such as site, size and number of biopsies, staining 
methods, proton pump inhibitor, antibiotics and experience of the examining 
pathologist [81]. The rapid urease test (RUT) is the most commonly used 
biopsy-based method to diagnose H. pylori infection because it is simple, 
rapid and accurate. However, it requires a high density of bacteria, and 
anything that reduces the bacterial load may produce false-negative tests 
[80,83]. Culturing of H. pylori from gastric biopsy specimen is a highly 
specific but less sensitive method. In general, culturing has almost 100% 
specificity, but the sensitivity of culture shows significant variation, between 
85-95% [81]. 
 The non-invasive tests as diagnostic tool in H. pylori infections of 
patients with various gastrointestinal disorders are strongly important 
because they make the endoscopy unnecessary in different situations [3]. 
Urea breath test (UBT) has been used for almost 30 years and is still the 
most popular and accurate noninvasive test for diagnosis of H. pylori 
infection. By the urease activity of H. pylori, the 
13
C- or 
14
C-labeled urea 
ingested by the patient is hydrolyzed to labeled CO2 in stomach, then labeled 
CO2 is absorbed in the blood and exhaled by breathing in which labeled CO2 
is measured [81]. Stools antigen test (SAT) is the other noninvasive method 
with good sensitivity and specificity (94% and 97%, respectively) in the 
diagnosis of H. pylori infection [81]. 
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 The pre-endoscopy screening may be performed principally through 
serological markers (detection of different kinds of immunoglobulins). For 
CagA detection, serology has proved to be useful, being CagA protein a 
factor with good antigenic properties, easy and reliable to perform and prone 
to reveal the presence of cag pathogenicity island [3,84]. Hsp60 is also a 
good antigen so that its detection can be performed through the appearance 
of specific antibodies against it [3,85].  
 The rapid and easy detection of virulent strains using novel PCR 
methods has been suggested as a mean to avoid the consequences of a long-
lasting untreated infection [3,80]. Real-time PCR is a sensitive, accurate 
method of diagnosing H. pylori infection. Compared to other available 
methods for diagnosing H. pylori for clinical and research purposes, PCR 
yields high sensitivity and specificity for H. pylori in frozen samples from 
patients with nonbleeding and bleeding peptic ulcer [86]. 
 A useful approach is to use the new and advanced multiplex PCR 
methods in gastric tissue samples, which could contribute to gain insights 
into the genotypic variability exhibited by this pathogen [3,80,87]. Novel 
ultra-sensitive methods as digital PCR could also contribute to detect cases 
of ―occult infection‖, which were traditionally considered as false-positive 
results in the 
13
C-urea breath test [88].  
 
6. Bacterial genetic diversity and role of mixed infections 
 
 The H. pylori genome (1.65 Mbp) codes for about 1,500 proteins [14]. 
H. pylori has been reported to be genetically extremely variable and this 
heterogeneity is proposed to be involved in the ability of H. pylori to cause 
different diseases [3,89,90], detrimental and non-detrimental chronic 
infections [3,7,91].  
 The remarkable adaptive capacity of H. pylori can be partly attributed to 
the enormous plasticity of its genome, caused by high mutation and 
recombination rates, and by the ability for aberrant genomic rearrangements 
and incorporation of non-homologous DNA. This results in an exceptionally 
high sequence diversity among strains that were isolated from unrelated 
human hosts and in an H. pylori core genome that consists of only 
approximately 1,100 genes, while the other approximately 400–500 genes 
per strain are strain-specific and variably present [92].  
 Strains of H. pylori exhibit considerable genetic diversity following a 
panmictic (non-clonal) population structure due to horizontal gene transfer 
and frequent recombination [21,22,93]. The estimated mutation rate reveals 
a mutation burst during the acute infection phase that is over 10 times faster 
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than the mutation rate during chronic infection, and orders of magnitude 
faster than mutation rates in any other bacteria. The elevated frequency of 
mutations in outer membrane protein genes suggests that the mutation burst 
facilitates rapid host adaptation of the bacteria [92]. 
 In a recent study, it has been suggested that prolonged in vivo exposure 
of H. pylori to the gastric environmental conditions associated with a high-
salt diet can lead to the emergence of strains adapted to these conditions. It 
has been shown that the production of proteins involved in iron acquisition 
and oxidative-stress resistance in H. pylori strains cultured from animals on 
high-salt diet differs from that of the input strain and strains isolated from 
animals on a regular diet [94]. 
 It seems that the number of H. pylori clones isolated from a single host 
varies depending on the geographic region and other factors as age, 
socioeconomic and hygienic status [16]. It has also been demonstrated the 
importance of mixed infections for the genetic diversification of H. pylori 
through recombination [95]. H. pylori mixed infections with facilitate 
interstrain gene transfer and the maintenance of genetic diversity for 
adaptation to the gastric environment, but whether mixed infections with 
histological significance and tissue tropism occur in the human stomach is 
still unclear [96].  
 Recent data suggest that around 23% of H. pylori-infected patients have 
mixed infections, with different dominant strains isolated from the antrum 
and the corpus specimens, and being mixed infection significantly related to 
the appearance of intestinal metaplasia in the antrum [96]. The role of mixed 
infections in the development of gastric cancer, however, deserves further 
investigation.  
 Mixed infection has also been described in the pediatric population [52]. 
It has been shown that the panmictic population structure of H. pylori results 
from very frequent recombination during mixed colonization by unrelated 
strains [97]. 
 Results of genetic studies comparing sequences of housekeeping genes 
have shown natural mixed infection in family members. Identical alleles 
found in some strains isolated from the children and parents, but not from 
unrelated patients, demonstrated that strains had circulated within the family. 
Several mechanisms, such as point mutations, intragenic recombination, and 
introduction of foreign alleles, were shown to enhance strain diversity within 
the family [13]. 
 Using enzyme-linked immunosorbent assay and line probe assay (LiPA) 
techniques, the prevalence of mixed H. pylori colonization was analyzed in 
127 subjects from Venezuela, a country of high H. pylori prevalence, from 
three regions representing different population groups: the Andes (Merida), 
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where Caucasian mestizos predominate, a major city near the coast 
(Caracas), where Amerindian-Caucasian-African mestizos predominate, and 
an Amazonian community (Puerto Ayacucho), where Amerindians 
predominate and mestizos reflect Amerindian and Caucasian ancestry. 
Among 121 H. pylori-positive persons, the prevalence of cagA-positive 
strains varied from 50% (Merida) to 86% (Puerto Ayacucho) by LiPA. Rates 
of mixed colonization also varied, as assessed by LiPA of the vacA s (mean, 
49%) and m (mean, 26%) regions. In total, 55% of the individuals had 
genotypic evidence of mixed colonization. vacA s1c, a marker of 
Amerindian (East Asian) origin, was present in all three populations, 
especially from Puerto Ayacucho (86%). These results demonstrate the high 
prevalence of mixed colonization and indicate that the H. pylori East Asian 
vacA genotype has survived in all three populations tested [1]. 
 
7. Research on new markers of H. pylori infection and 
progression 
 
 The low incidence of severe disease associated with infection has 
suggested that there may be ―beneficial‖ H. pylori organisms in addition to 
those that cause disease. In fact, since humans have co-evolved with                  
H. pylori, they might derive some benefits from them [3,98]. Certainly, man 
adapts physiologically to infection during his lifetime and treatment can lead 
to problems such as reflux oesophagitis. In view of these real problems, it 
would seem preferable to screen for and treat only strains that are known to 
cause disease. In H. pylori a lot of virulence determinants have been detected 
affecting the infection course [3]. To date, despite intensive research, not 
enough knowledge exit on clear risk or disease-specific markers [99]. 
 Recent studies have analysed miRNA expression in human H. pylori-
infected patients with or without duodenal ulcer disease. Results obtained 
have shown that a set of miRNA are deregulated during chronic gastric 
inflammation and could be useful as a surrogate marker for determining the 
presence of H. pylori [99]. 
 In our research group, we have amplified and sequenced six 
housekeeping genes (amiA, cgt, cpn60, cpn70, dnaJ, and luxS) related to H. 
pylori pathogenesis to evaluate their usefulness for the specific detection of 
H. pylori, the genetic discrimination at strain level and the detection of 
multiple infection. A total of 52 H. pylori clones, isolated from 14 gastric 
biopsies from 11 patients, were analyzed for this purpose [93]. 
 All genes were specifically amplified for H. pylori and all clones 
isolated from different patients were discriminated, with gene distances 
ranged from 0.9 to 7.8%. Although most clones isolated from the same 
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patient showed identical gene sequences, an event of multiple infection was 
detected in all the genes and microevolution events were showed for amiA 
and cpn60 genes [93]. 
 These results suggest that housekeeping genes could be useful for                 
H. pylori detection and to elucidate the mode of transmission and the 
relevance of the multiple infection [93]. These genes are potential candidates 
to detect H. pylori infection in gastric biopsies and other specimens (as 
gastric juice, stool, saliva, dental plaque, water, and food samples), together 
with others, mainly used for gastric biopsies, as ureA, vacA, 16S rRNA, and 
23S rRNA genes, previously described [81,86,93]. 
 In our study, two different strains isolated from the antral biopsy B657A 
were clearly detected by all genes with high distance values (1.6–7.3%). One 
strain was represented by the identical clones B657A-1, -2 and -3, and the 
other strain by the clone B657A-4, which was identical to clones isolated 
from B657C (corpus biopsy from the same patient), except in the case of 
amiA. This high divergence observed between both strains indicates an event 
of multiple infection in the antrum of the stomach [93]. Since the role of 
multiple infections on disease outcome and progression is still unclear 
[1,13,93,96], we consider that the genes sequenced in our study could be 
used in further research in this issue.  
 Of note, concatenation of amiA, cgt, cpn60, cpn70, dnaJ, and luxS 
partial sequences allowed us to conduct a multilocus sequence analyses 
(MLSA) approach, which is useful to elucidate intra- and interspecies 
phylogenetic relationships [93,100,101] and, in the case of H. pylori, the 
phylogeographic differentiation of bacterial populations associated to the 
migration of human populations [18,21,93]. Most of these genes had never 
been used for these purposes before, except dnaJ and, especially, cpn60, a 
gene useful for microbial phylogeny, detection and identification, ecology, 
and evolution through the analysis of the 555 bp region known as universal 
target (UT) analyzed in our study [93,102,103].  
 In conclusion, our results provide new tools for the detection of            
H. pylori, with potential applications for H. pylori detection in different 
specimens and to assess the mode of transmission, the role associated to 
virulence or the phylogeographic differentiation of H. pylori populations 
[93].  
 
8. Conclusions 
 
 Stomach cancer is one of the leading causes of cancer death worldwide, 
despite its incidence and mortality falling in many places. The discovery in 
1984 that a bacterial infection with H. pylori could cause stomach and 
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duodenal ulcers prompted work in its role in causing gastritis, and led to the 
first prospective study in 1991 by Forman et al., showing that infection with 
H. pylori increased the risk of stomach cancer in those infected by almost 
three-fold [104]. 
 Efforts to reduce the incidence of gastric cancer by means of eradicating 
H. pylori have been variable (because of re-infections) and there is still the 
debate around population screening and opportunistic ―seek and treat‖ of    
H. pylori in the absence of symptoms [104]. Instead, it would seem 
preferable to screen for and treat only strains that are known to cause 
disease, as a promise targeted intervention [3,104].  
 Research on the bacterial virulence factors, effects of H. pylori on 
epithelial cells, genetic polymorphism of both the bacterium and its host, and 
the environmental factors can help to understand the role of this bacterium in 
gastric carcinogenesis [9]. 
 Other challenging issues, needing further research, are the elucidation of 
transmission, implication of H. pylori in other diseases, the role of mixed 
infections, the development of new sensitive and specific PCR methods for 
H. pylori detection in gastric samples and other specimens, and the 
development of a safe and efficient preventive vaccine that could address the 
wide diversity of strains.  
 In this context, results of our genetic study from H. pylori clones 
isolated from gastric biopsies can contribute to the advances in all these 
fields. Our results suggest that housekeeping genes could be useful for        
H. pylori detection and to elucidate the mode of transmission and the 
relevance of multiple infection [93]. We consider that further genetic studies, 
including sequencing of complete genomes of virulent strains and 
metagenomics, will provide powerful tools to face all current unmet 
challenges of H. pylori infection.  
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